KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insulet (PODD) Deferred Taxes (2023 - 2026)

Insulet posted quarterly Deferred Taxes of $7.0 million for Q1 2026, up 133.33% year-on-year from $3.0 million in Q1 2025, and down 64.1% on a QoQ basis from $19.5 million in Q4 2025.

Insulet (PODD) has 4 years of Deferred Taxes data on file, last reported at $7.0 million in Q1 2026.

  • For the quarter ending Q1 2026, Deferred Taxes rose 133.33% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $66.2 million (up 1103.64% YoY), and the FY2025 full-year result was $62.2 million, up 145.43% from the prior year.
  • Deferred Taxes for Q1 2026 stood at $7.0 million, down from $19.5 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $35.7 million in Q3 2025 and bottomed at -$1.6 million in Q3 2024.
  • The 4-year median for Deferred Taxes is $4.0 million (2024), against an average of $9.0 million.
  • The widest annual swing landed in 2025, when Deferred Taxes surged 2331.25%; it then soared 133.33% in 2026.
  • A 4-year view of Deferred Taxes shows it stood at $200000.0 in 2023, then jumped by 1850.0% to $3.9 million in 2024, then jumped by 400.0% to $19.5 million in 2025, then plunged by 64.1% to $7.0 million in 2026.
  • The last three Deferred Taxes figures came in at $7.0 million (Q1 2026), $19.5 million (Q4 2025), and $35.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -33.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -101.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -351.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -9.40 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 300,000.00
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -16.70 Mn
10 Insulet 10.37 Bn 9.89 Bn 529.10 Mn 7.00 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 7.00 Mn
Dec 31, 2025 19.50 Mn
Sep 30, 2025 35.70 Mn
Jun 30, 2025 4.00 Mn
Mar 31, 2025 3.00 Mn
Dec 31, 2024 3.90 Mn
Sep 30, 2024 -1.60 Mn
Dec 31, 2023 200,000.00